Boston ScientificHAM:BSX -0.48%74 EBITDA Margin % is 30.81% as of Mar. 2026, which is 41% above its 10-year median of 21.92. GuruFocus rates HAM:BSX with a GF Score™ of 74/100 and a GF Value™ of €90.64 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 816 Medical Devices & Instruments companies, Boston Scientific ranks better than 86.76% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Boston Scientific's EBITDA for the
three
months ended in Mar. 2026 was €1,387 Mil. Boston Scientific's Revenue for the
three
months ended in Mar. 2026 was €4,501 Mil. Therefore, Boston Scientific's EBITDA margin for the quarter that ended in Mar. 2026 was 30.81%.
Boston Scientific (HAM:BSX) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Boston Scientific EBITDA Margin % Related Terms
Boston Scientific EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Boston Scientific's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:BSX vs EW, MDT, DXCM: EBITDA Margin % Comparison
For the Medical Devices subindustry, Boston Scientific's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boston Scientific EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Boston Scientific's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boston Scientific (HAM:BSX) has a EBITDA Margin % of 30.81% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Boston Scientific and its competitors. This is 41% above median its historical median of 21.92. Over the past decade, Boston Scientific's EBITDA Margin % has ranged from 14.17 to 26.65. According to the industry distribution chart, Boston Scientific ranks #108 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 13.2%.
Is Boston Scientific's EBITDA Margin % too high?
Boston Scientific's current EBITDA Margin % of 30.81% is 41% above median its 10-year median of 21.92. Over the past 10 years, this metric has ranged from a low of 14.17 to a high of 26.65. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Boston Scientific's value of 30.81% is 312.2% above this industry median. Based on the distribution chart, Boston Scientific ranks #108 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Boston Scientific has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Boston Scientific's EBITDA Margin % compare to EW and MDT?
According to the Medical Devices & Instruments industry distribution chart, Boston Scientific ranks #108 out of 816 companies for EBITDA Margin %. This places Boston Scientific in the top 13% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Boston Scientific's value of 30.81% is 312.2% above this benchmark. Historically, Boston Scientific's own EBITDA Margin % has ranged from 14.17 to 26.65 over the past decade. While the company's 10-year median is 21.92 vs. the industry median of 7.48, Boston Scientific has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boston Scientific's current EBITDA Margin % of 30.81% is 312.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Boston Scientific and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boston Scientific's current EBITDA Margin % is 30.81%, which is 41% above median its own 10-year median of 21.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boston Scientific stock overvalued right now?
Based on GuruFocus' analysis, Boston Scientific (HAM:BSX) is currently considered Significantly Undervalued. The stock's GF Value™ is €90.64, compared to a current price of €38.02 — trading 58.1% below its estimated fair value. The current EBITDA Margin % is 30.81%, which is 41% above median its 10-year median of 21.92 and 312.2% above the Medical Devices & Instruments industry median of 7.48. Boston Scientific's overall GF Score™ is 74/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Boston Scientific (HAM:BSX), the current EBITDA Margin % is 30.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boston Scientific (HAM:BSX) Overvalued in 2026?
Based on GuruFocus' analysis, Boston Scientific stock appears to be undervalued.
The current stock price of €38.02 is trading 58.1% below its estimated GF Value™ of €90.64.
GuruFocus considers Boston Scientific to be Significantly Undervalued.
Key valuation signals for HAM:BSX:
EBITDA Margin %: 30.81% (41% above median its 10-year median of 21.92)
GF Value™: €90.64 vs. price of €38.02 (58.1% below fair value)
Industry Position: 312.2% above the Medical Devices & Instruments median (#108 of 816)
No single metric tells the full story. See the HAM:BSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
74GF Score
Get the complete analysis for HAM:BSX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:BSX has been successfully added to your 
